BASIC DETERMINANTS OF MELANOMA STEM CELL
https://doi.org/10.17650/1726-9784-2015-14-2-7-16
Abstract
Keywords
About the Authors
A. A. VartanianRussian Federation
M. V. Oborotova
Russian Federation
References
1. Abdullah L.N., Chow E.K. Mechanisms of chemoresistance in cancer stem cells // Clin. Transl. Med. - 2013. -17. - P. 3-14.
2. Barnhill R.L., Fine J.A., Roush GC. et al. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study // Cancer. - 1996. - 78. - P. 427-32.
3. Becker M.W., Jordan C.T. Leukemia stem cells in 2010: current understanding and future directions // Blood Rev. - 2011. - 25(2). - P. 75-81.
4. Boiko A.D., Razorenova O.V., van de Rijn M. et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271 // Nature. - 2010. - 466. - P. 133-7.
5. Bu Y., Cao D. The origin of cancer stem cells // Front Biosci. - 2012. - 4. - P. 819-30.
6. Clarke M.F., Dick J.E., Dirks P.B. et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells // Cancer Res. - 2006. - 66. - P. 9339-44.
7. Dirks P. Cancer stem cells: invitation to a second round // Nature. - 2010. - 466. - P. 40-1.
8. Dou J., He X., Liu Y. et al. Effect of downregulation of ZEB1 on vimentin expression, tumour migration and tumourigenicity of melanoma B16F10 cells and CSCs // Cell Biol. Int. - 2014. - 38(4). - P. 452-61.
9. Eaves C.J. Cancer stem cells: here, there, everywhere? // Nature. - 2008. - 456. - P. 581-3.
10. Elliott A.M., Al-Hajj M.A. ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome // Mol. Cancer Res. - 2009. - 7. - P. 79-87.
11. Fan T.Z., Sun W. Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy // World J. Gastrointest. Surg. - 2010. - 2. - P. 117-27.
12. Fang D., Nguyen T.K., Leishear K. et al. A tumorigenic subpopulation with stem cell properties in melanomas // Cancer Res. - 2005. - 65. - P. 9328-37.
13. Frank N.Y., Margaryan A., Huang Y. et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma // Cancer Res. - 2005. - 65. - P. 4320-33.
14. Frank N.Y., Schatton T., Kim S. et al. VEGFR-1 expressed by malignant melanoma initiating cells is required for tumor growth // Cancer Res. - 2011. - 71. - P. 1474-85.
15. Fukuda S., Pelus L.M. Survivin, a cancer target with an emerging role in normal adult tissues // Mol. Cancer Ther. - 2006. - 5(5). - P. 1087-98.
16. Fulawka L., Donizy P., Halon A. Cancer stem cells - the current status of an old concept: literature review and clinical approaches // Biol. Res. - 2014. - 47(1). - P. 66-75.
17. Greene J.M., Levy D., Fung K.L. et al. Modeling intrinsic heterogeneity and growth of cancer cells //J. Theor. Biol. - 2015. - 367. - P. 262-77.
18. Gupta T., Nair V., Jalali R. Stem cell niche irradiation in glioblastoma: providing a ray of hope? // CNS Oncol. - 2014. - 3(5). - P. 367-76.
19. Hsu M.Y., Meier F., Herlyn M. Melanoma development and progression: a conspiracy between tumor and host // Differentiation. - 2002. - 70. - P. 522-36.
20. http://www.nhgri.nih.gov/DIR/microarray/MelanomaSupplement/index.htmI.
21. Kallioniemi A. Bone morphogenetic protein 4-a fascinating regulator of cancer cell behavior // Cancer Genet. - 2012. - 205(6). - P. 267-77.
22. Kartal-Yandim M., Adan-Gokbulut A., Baran Y. Molecular mechanisms of drug resistance and its reversal in cancer // Cri.t Rev. Biotechnol. - 2015. - 1. - P. 11-8.
23. Kasai T., Chen L., Mizutani A. et al. Cancer stem cells converted from pluripotent stem cells and the cancerous niche // J Stem Cells Regen Med. - 2014. - 10(1). - P. 2-7.
24. Kathawala R.J., Gupta P., Ashby C.R. et al. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade // Drug Resist Updat. - 2015. - 18. - P. 1-17.
25. Kelly P.N., Dakic A., Adams J.M. et al. Tumor growth need not be driven by rare cancer stem cells // Science. - 2007. - 317. - P. 337-45.
26. Khong H.T., Wang Q.J., Rosenberg S.A. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression //J. Immunother. - 2004. - 27. - P. 184-90.
27. Klein C.A. Parallel progression of primary tumours and metastases //Nat. Rev. Cancer. - 2009 - 9(4). - P. 302-12.
28. Kreso A., Dick J.E. Evolution of the cancer stem cell model //Cell Stem Cell. - 2014. - 14(3). - P. 275-91.
29. Lang D., Mascarenhas J.B., Shea C.R. Melanocytes, melanocyte stem cells, and melanoma stem cells // Clin. Dermatol. - 2013. - 31(2). - P. 166-78.
30. Lee P.P., Yee C., Savage P.A. et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients//Nat. Med. - 1999. - 5. - P. 677-85.
31. Li A. The biology of melanocyte and melanocyte stem cell // Acta Biochim. Biophys. Sin. - 2014. - 46(4). - P. 255-60.
32. Liao W.T., Ye Y.P., Deng Y.J. et al. Metastatic cancer stem cells: from the concept to therapeutics // Am. J. Stem. Cells. - 2014. - 3(2). - P. 46-62.
33. Lucero O.M., Dawson D.W., Moon R.T. et al. Are-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers//Curr. Oncol. Rep. - 2010. - 12(5). - P. 314-8.
34. Maniotis A.J., Folberg R., Hess A. et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry // Am. J. Pathol. - 1999. - 155(3). - P. 739-52.
35. Martello G., Smith A. The nature of embryonic stem cells // Annu. Rev. Cell Dev. Biol. - 2014. - 30. - P. 647-75.
36. McAllister J.C., Zhan Q., Weishaupt C. et al. The embryonic morphogen, Nodal, is associated with channellike structures in human malignant melanoma xenografts //J. Cutan. Pathol. - 2010. - 37(Suppl 1). - P. 19-25.
37. Monzani E., Facchetti F., Galmozzi E. et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential // Eur. J. Cancer. - 2007. - 43. - P. 935-46.
38. Monzani E., La Porta C.A. Targeting cancer stem cells to modulate alternative vascularization mechanism // Stem. Cell Rev. - 2008. - 4. - P. 51-6.
39. Nguyen D.X., Bos P.D., Massagué J. Metastasis: from dissemination to organ-specific colonization //Nat. Rev. Cancer. - 2009. - 9(4). - P. 274-84.
40. Nowel P.C. The clonal evolution of tumor cell population // Science. - 1976. - 194. - P. 23-8.
41. Paulis Y.W., Soetekouw P.M., Verheul H.M. et al. Signalling pathways in vasculogenic mimicry // Biochim Biophys Acta. - 2010. - 1806(1). - P. 18-28.
42. Pawelek J.M. Fusion of bone marrow-derived cells with cancer cells: metastasis as a secondary disease in cancer // Chin. J. Cancer. - 2014. - 33(3). - P. 133-9.
43. Plaks V., Kong N., Werb Z. The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells? // Cell Stem Cell. - 2015. - 16(3). - P. 225-38.
44. Quintana E., Shackleton M., Foster H.R. et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized //Cancer Cell. - 2010. - 18. - P. 510-23.
45. Ramalho-Santos M., Willenbring H. On the origin of the term ‘stem cell’//Cell Stem Cell. - 2007. - 1. - P. 35-8.
46. Rappa G., Fodstad O., Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma //Stem Cells. - 2008. - 26. - P. 3008-17.
47. Regad T. Molecular and cellular pathogenesis of melanoma initiation and progression //Cell Mol Life Sci. - 2013. - 70(21). - P. 4055-65.
48. Rothhammer T., Bataille F., Spruss T. et al. Functional implication of BMP4 expression on angiogenesis in malignant melanoma //Oncogene. - 2007. - 26. - P. 4158-70.
49. Scadden D.T. Nice neighborhood: emerging concepts of the stem cell niche // Cell. - 2014. - 157(1). - P. 41
50. Schatton T., Murphy G.F., Frank N.Y. et al. Identification of cells initiating human melanomas //Nature. -2008. - 451. - P. 345-9.
51. Schatton T., Frank M.H. Antitumor immunity and cancer stem cells // Ann NY Acad Sci. - 2009. - 1176. - P. 154-69.
52. Schatton T., Schutte U., Frank N.Y. et al. Modulation of T-cell activation by malignant melanoma initiating cells //Cancer Res. - 2010. - 70. - P. 697-708.
53. Sebastian C. Tracking down the origin of cancer: metabolic reprogramming as a driver of stemness and tu-morigenesis // Crit. Rev. Oncog. - 2014. - 19(5). - P. 363-82.
54. Shiozawa Y., Nie B., Pienta K.J. et al. Cancer stem cells and their role in metastasis // Pharmacol Ther. - 2013. - 138(2). - P. 285-93.
55. Situm M., Buljan M., Kolić M. et al. Melanoma--clinical, dermatoscopical, and histopathological morphological characteristics //Acta Dermatovenerol Croat. - 2014. - 1. - P. 1-12.
56. Skvortsov S., Debbage P, Lukas P, Skvortsova I. Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways // Semin. Cancer Biol. - 2015. - 31. - P. 36-42.
57. Sun B., Zhang D., Zhan S. et al. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma // Cancer. - 2007. - 249. - P. 188-97.
58. Takeuchi H., Kuo C., Morton D.L. et al. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas // Cancer Res. - 2003. - 63. - P. 441-48.
59. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S. et al. Embryonic stem cell lines derived from human blastocysts // Science. - 1998. - 282. - P. 1145-7.
60. Tomasetti C., Vogelstein B., Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation // Proc. Natl. Acad. Sci. USA. - 2013. - 110(6). - P. 1999-2004.
61. Tomasetti C., Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions // Science. -2015. - 347(6217). - P. 78-81.
62. Topczewska J.M., Postovit L.M., Margaryan N.V. et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness // Nat. Med. - 2006. - 12. - P. 925-32.
63. Van der Schaft D.W., Seftor, R., Seftor E.A. et al. Effect of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells // J. Natl. Cancer Inst. - 2004. - 96. - P. 1473-77.
64. van Houdt I.S., Sluijter B.J., Moesbergen L.M. et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression // Int. J. Cancer. - 2008. - 123. - P. 609-15.
65. Vartanian A.A., Burova O.S., Stepanova E.V. et al. The involvement of apoptosis in melanoma vasculogenic mimicry//Melanoma Res. - 2007. - 1. - P. 1-8.
66. Vartanian A., Stepanova E., Grigorieva I. et al. VEGFR1 and PKCœ signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner // Melanoma Res. - 2011. - 21(2). - P. 91-8.
67. Vartanian A., Gatsina G., Grigorieva I. et al. The involvement of Notch signaling in melanoma vasculogenic mimicry // Clin. Exp. Med. - 2013. - 13(3). - P. 201-9.
68. Wang K., Zhang T., Dong Q. et al. Redox homeostasis: the linchpin in stem cell self-renewal and differentiation // Cell Death Dis. - 2013. - 4. - e537-e346.
69. Watabe T., Miyazono K. Roles of TGF-beta family signaling in stem cell renewal and differentiation // Cell Res. - 2009. - 19(1). - 103-15.
Review
For citations:
Vartanian A.A., Oborotova M.V. BASIC DETERMINANTS OF MELANOMA STEM CELL. Russian Journal of Biotherapy. 2015;14(2):7-16. (In Russ.) https://doi.org/10.17650/1726-9784-2015-14-2-7-16